<DOC>
	<DOCNO>NCT00168922</DOCNO>
	<brief_summary>Determination response rate Assessment toxicity determination `` time progression ''</brief_summary>
	<brief_title>Study Determine Efficacy Bendamustin Patients With Recurrent Small Cell Lung Cancer ( SCLC )</brief_title>
	<detailed_description>Phase II Study determine efficacy Bendamustin ( Ribomustin ) patient recurrent small cell bronchial carcinoma cytostatic polychemotherapy</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Bendamustine Hydrochloride</mesh_term>
	<criteria>Patients histological proven , curative non treatable small lung cell carcinoma Recurrence &gt; 8 week , &gt; 1 year 1st line treatment platin etoposide polychemotherapy , without brain metastasis Brain metastasis WHOPS 3 4</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2001</verification_date>
	<keyword>recurrent SCLC</keyword>
</DOC>